11.62

1.71% 0.195

After Hours: 11.70 0.085 +0.73%

Liquidia Corp (LQDA)

Overview News Price History Option Chain Financials Discussions Forecast

Liquidia Corp stock is traded at $11.62, with a volume of 474.56K. It is up +1.71% in the last 24 hours and up +5.50% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Previous Close:

$11.42

Open:

$11.44

24h Volume:

474.56K

Relative Volume:

0.53

Market Cap:

$975.44M

Revenue:

$17.49M

Net Income/Loss:

$-78.50M

P/E Ratio:

-15.08

EPS:

-0.77

Net Cash Flow:

$-52.85M

1W Performance:

+14.77%

1M Performance:

+5.50%

6M Performance:

-6.48%

1Y Performance:

+69.07%

1-Day Range:

$11.33

$11.65

1-Week Range:

$9.93

$11.65

52-Week Range:

$6.82

$16.99

Liquidia Corp Stock (LQDA) Company Profile

Name

Liquidia Corp

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

919.328.4400

Address

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC

Employee

145

Twitter

@Liquidia_Inc

Next Earnings Date

2024-11-05

Latest SEC Filings

LQDA's Discussions on Twitter

Compare LQDA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LQDA Liquidia Corp	11.62	975.44M	17.49M	-78.50M	-52.85M	-0.77
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy
Sep-19-22	Resumed	Wedbush	Underperform
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform
Jul-22-22	Initiated	Ladenburg Thalmann	Buy
May-31-22	Initiated	BTIG Research	Buy
May-26-22	Initiated	BofA Securities	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform
Aug-20-18	Initiated	Jefferies	Buy
Aug-20-18	Initiated	Needham	Buy

View All

Liquidia Corp Stock (LQDA) Latest News

Nov 22, 2024

Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Nov 22, 2024

Nov 18, 2024

Liquidia (NASDAQ:LQDA) Receives Buy Rating from Needham & Company LLC - MarketBeat

Nov 14, 2024

The Analyst Landscape: 11 Takes On Liquidia - Benzinga

Nov 14, 2024

Liquidia Corporation (NASDAQ:LQDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Q3 2024 Liquidia Corp Earnings Call Transcript - GuruFocus.com

Nov 14, 2024